Trump’s Plans to Lower Drug Costs Remain Mystery to Congress

White House Keeps Congress in Dark About Trump’s Plan to Lower Drug Costs
– Inside Health Policy

Manatt’s Ian Spatz, a senior advisor with Manatt Health, was quoted by Inside Health Policy for an article examining the administration’s plan to lower the cost of prescription drugs.

According to the publication, Congress has not been privy to the specifics of President Trump’s plan to lower costs. Spatz explained that it is uncommon for White House officials to keep details of a big announcement secret from Congress.

“I found that surprising, based on my Washington experience, that there wouldn’t be more coordination with the Hill to basically guarantee a good reaction,” he explained.



pursuant to New York DR 2-101(f)

© 2020 Manatt, Phelps & Phillips, LLP.

All rights reserved